|Articles|May 23, 2018
The Fundamental Disconnect Between Pharma and Technology
Author(s)Michelle Maskaly
Otsuka Pharmaceutical’s President and CEO of Development and Commercialization William Carson explains the initial growing pains the company went through with their technology company partner in the early development stages of the first U.S. FDA approved digital medicine system.
Advertisement
Otsuka Pharmaceutical’s President and CEO of Development and Commercialization William Carson explains the initial growing pains the company went through with their technology company partner in the early development stages of the first U.S. FDA approved digital medicine system, Abilify Mycite.
His interview was recorded during the May 2018 Financial Times Live ‘s US Healthcare & Life Sciences Summit in New York City.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
DARPA's Role in Bringing Manufacturing Back to the US
2
FDA Pilot Targets Faster Early-Stage Drug Trial Starts
3
The Next Evolution of Class of Trade: Why Customer Identity Is Becoming Market Access’s Hardest Problem
4
Pharmaceutical Executive Daily: FDA Pilot Targets Faster Early-Stage Drug Trial Starts
5